Cassava Sciences, Inc. (SAVA)
SAVA Stock Price Chart
Explore Cassava Sciences, Inc. interactive price chart. Choose custom timeframes to analyze SAVA price movements and trends.
SAVA Company Profile
Discover essential business fundamentals and corporate details for Cassava Sciences, Inc. (SAVA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Jul 2000
Employees
30.00
Website
https://www.cassavasciences.comCEO
Richard Jon Barry
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
SAVA Financial Timeline
Browse a chronological timeline of Cassava Sciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 13 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.18 .
Earnings released on 8 May 2025
EPS came in at -$0.48 .
Earnings released on 3 Mar 2025
EPS came in at -$0.57 surpassing the estimated -$0.68 by +16.18%.
Earnings released on 7 Nov 2024
EPS came in at -$0.58 surpassing the estimated -$1.37 by +57.66%.
Earnings released on 8 Aug 2024
EPS came in at -$1.28 falling short of the estimated -$0.44 by -190.91%.
Earnings released on 10 May 2024
EPS came in at -$1.41 falling short of the estimated -$0.51 by -176.47%.
Earnings released on 28 Feb 2024
EPS came in at -$0.50 falling short of the estimated -$0.40 by -25.00%, while revenue for the quarter reached $2.35M .
Earnings released on 7 Nov 2023
EPS came in at -$0.61 surpassing the estimated -$0.90 by +32.22%.
Earnings released on 3 Aug 2023
EPS came in at -$0.63 falling short of the estimated -$0.58 by -8.62%.
Earnings released on 1 May 2023
EPS came in at -$0.58 falling short of the estimated -$0.56 by -3.57%.
Earnings released on 28 Feb 2023
EPS came in at -$0.47 surpassing the estimated -$0.58 by +18.97%, while revenue for the quarter reached -$1.80K .
Earnings released on 7 Nov 2022
EPS came in at -$0.51 falling short of the estimated -$0.47 by -8.51%.
Earnings released on 3 Aug 2022
EPS came in at -$0.48 falling short of the estimated -$0.42 by -14.29%.
Earnings released on 5 May 2022
EPS came in at -$0.44 falling short of the estimated -$0.43 by -2.33%.
Earnings released on 28 Feb 2022
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%, while revenue for the quarter reached -$200.00 .
Earnings released on 10 Nov 2021
EPS came in at -$0.24 falling short of the estimated -$0.17 by -41.18%.
Earnings released on 3 Aug 2021
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%.
Earnings released on 21 Apr 2021
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 23 Mar 2021
EPS came in at -$0.09 falling short of the estimated -$0.05 by -80.00%.
Earnings released on 9 Nov 2020
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
SAVA Stock Performance
Access detailed SAVA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.